Data completeness
1/8 — Limited
PERCORTEN by Novartis is clinical pharmacology: desoxycorticosterone pivalate (docp), like other adrenocorticoid hormones, is thought to act by controlling the rate of synthesis of proteins.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERCORTEN (desoxycorticosterone pivalate/DOCP) is a long-acting mineralocorticoid ester administered via intramuscular injection for treatment of hypoadrenocorticism in animals. It works by mimicking aldosterone's effects on renal tubular sodium reabsorption, potassium excretion, and extracellular fluid volume expansion to prevent hypotensive shock and pre-renal azotemia. The drug acts through steroid-receptor complex formation in the cytoplasm, nuclear translocation, and DNA transcription to induce specific protein synthesis.
Pre-Launch
Pre-launch stage indicates active recruitment for commercial team building, launch planning, and regulatory affairs roles at Novartis.
Mechanism of Action
CLINICAL PHARMACOLOGY: Desoxycorticosterone pivalate (DOCP), like other adrenocorticoid hormones, is thought to act by controlling the rate of synthesis of proteins. It reacts with receptor proteins in the cytoplasm to form a steroid-receptor complex. This complex moves into the nucleus, where it…
Worked on PERCORTEN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.